HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims & Hers - The complaint states that Hims failed to disclose that its communication with Novo Nordisk would not ensure a long-term collaboration for access to Wegovy for its subscribers [4]. - It is alleged that Novo did not approve Hims' offerings of compounded semaglutide products, contradicting Hims' positive statements about the partnership [4]. - The lawsuit highlights that Hims misrepresented the availability of branded Wegovy alongside compounded semaglutide options, which could mislead investors about user choice and access [4].